Cytarabine

Generic Name: Cytarabine

Brand Names: Cytosar, Vyxeos

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₃O_₅

CAS Number: 147-94-4

Unique Ingredient Identifier: 04079A1RDZ

Background: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication: For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Associated Therapies: -

Clinical Trials

Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia

Phase 4

Completed

Conditions: Acute Lymphobkastic Leukemia

Interventions: Drug: Vincristine
Drug: Daunorubicin
Drug: Prednisone
Drug: L-asparaginase
Drug: Ciclophosphamide
Drug: Metotrexate
Drug: ARA-C
Drug: Hidrocortisone
Drug: Mercaptopurine
Drug: VP-16
Drug: Dexametasone

First Posted Date: 2014-01-15

Last Posted Date: 2020-03-05

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 107

Registration Number: NCT02036489

Locations: 🇪🇸
Hospital Germans Trias i Pujol, Barcelona, Spain

Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 1

Completed

Conditions: Chronic Myelomonocytic Leukemia-2
Acute Myeloid Leukemia
High Risk Myelodysplastic Syndrome
Myeloproliferative Neoplasm

Interventions: Drug: Cytarabine
Drug: Daunorubicin Hydrochloride
Drug: Etoposide
Drug: Idarubicin Hydrochloride
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Pomalidomide

First Posted Date: 2014-01-08

Last Posted Date: 2020-10-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT02029950

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 2

Terminated

Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Untreated Adult Acute Myeloid Leukemia
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)

Interventions: Drug: cytarabine
Drug: omacetaxine mepesuccinate
Drug: decitabine
Other: laboratory biomarker analysis

First Posted Date: 2014-01-07

Last Posted Date: 2016-05-09

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 2

Registration Number: NCT02029417

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy

Phase 4

Conditions: Acute Myeloid Leukemia
AML1-ETO Fusion Protein Expression

Interventions: Drug: Fludarabine
Drug: Cytarabine

First Posted Date: 2013-12-31

Last Posted Date: 2013-12-31

Lead Sponsor: Changhai Hospital

Target Recruit Count: 62

Registration Number: NCT02024308

Locations: 🇨🇳
Department of Hematology, Changhai Hospital, Shanghai, China

Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)

Phase 3

Completed

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: Cytarabine
Drug: Dasatinib
Drug: Daunorubicin
Drug: Idarubicin

First Posted Date: 2013-12-17

Last Posted Date: 2024-02-23

Lead Sponsor: University of Ulm

Target Recruit Count: 204

Registration Number: NCT02013648

Locations: 🇦🇹
Hanuschkrankenhaus, Wien, Austria
🇦🇹
Krankenhaus der Barmherzigen Schwestern, Linz, Austria
🇦🇹
Universitätsklinik der PMU, Salzburg, Austria

and more 51 locations

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

Phase 3

Active, not recruiting

Conditions: Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Biospecimen Collection
Biological: Blinatumomab
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Daunorubicin
Drug: Daunorubicin Hydrochloride
Drug: Dexamethasone
Drug: Etoposide
Drug: Leucovorin Calcium
Procedure: Lumbar Puncture
Drug: Mercaptopurine
Drug: Methotrexate
Drug: Pegaspargase
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine
Drug: Vincristine Sulfate
Procedure: X-Ray Imaging

First Posted Date: 2013-12-06

Last Posted Date: 2024-12-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 488

Registration Number: NCT02003222

Locations: 🇺🇸
Banner North Colorado Medical Center, Greeley, Colorado, United States
🇺🇸
Good Samaritan Hospital - Cancer Centers of Colorado, Lafayette, Colorado, United States
🇺🇸
Banner McKee Medical Center, Loveland, Colorado, United States

and more 545 locations

Pilot Study Efficacy and Tolerance Fish Oil Emulsion Daunorubicin and Cytarabine Treatment of AML Younger Patients

Phase 2

Completed

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: OMEGAVEN
Drug: Daunorubicin
Drug: Cytarabine

First Posted Date: 2013-12-03

Last Posted Date: 2018-04-27

Lead Sponsor: French Innovative Leukemia Organisation

Target Recruit Count: 30

Registration Number: NCT01999413

Locations: 🇫🇷
Emmanuel GYAN, Tours, France

Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

Phase 2

Completed

Conditions: Anaplastic Large Cell Lymphoma, ALK-Positive
Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma
Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma
Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma

Interventions: Drug: Crizotinib
Drug: Brentuximab Vedotin
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dexamethasone
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Drug: Ifosfamide
Drug: Methotrexate

First Posted Date: 2013-11-08

Last Posted Date: 2024-04-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 137

Registration Number: NCT01979536

Locations: 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸
Valley Children's Hospital, Madera, California, United States
🇺🇸
Naval Medical Center - Portsmouth, Portsmouth, Virginia, United States

and more 151 locations